Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
98.40
-1.24 (-1.24%)
At close: Mar 6, 2026, 4:00 PM EST
98.30
-0.10 (-0.10%)
After-hours: Mar 6, 2026, 5:48 PM EST
Revolution Medicines Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Revolution Medicines stock have an average target of 114.63, with a low estimate of 64 and a high estimate of 170. The average target predicts an increase of 16.49% from the current stock price of 98.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 8 | 8 | 8 |
| Buy | 6 | 9 | 9 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 18 | 18 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $75 → $120 | Buy | Maintains | $75 → $120 | +21.95% | Feb 26, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $100 → $144 | Buy | Maintains | $100 → $144 | +46.34% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Maintains $150 → $145 | Strong Buy | Maintains | $150 → $145 | +47.36% | Feb 26, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $92 → $122 | Buy | Maintains | $92 → $122 | +23.98% | Feb 2, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $75 → $150 | Buy | Maintains | $75 → $150 | +52.44% | Jan 27, 2026 |
Financial Forecast
Revenue This Year
38.64M
Revenue Next Year
251.99M
from 38.64M
Increased by 552.08%
EPS This Year
-6.76
from -5.95
EPS Next Year
-6.07
from -6.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 200.3M | 636.5M | |||
| Avg | 38.6M | 252.0M | |||
| Low | n/a | 50.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 1,547.1% | |||
| Avg | - | 552.1% | |||
| Low | - | 31.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.30 | -1.35 | |||
| Avg | -6.76 | -6.07 | |||
| Low | -7.58 | -8.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.